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Abstract
Juvenile dermatomyositis (JDM) is an immune-mediated inflammatory disease affecting the microvasculature of skin and
muscle. CD4+CD25+FOXP3+ regulatory T cells (Tregs) are key regulators of immune homeostasis. A role for Tregs in JDM
pathogenesis has not yet been established. Here, we explored Treg presence and function in peripheral blood and muscle
of JDM patients. We analyzed number, phenotype and function of Tregs in blood from JDM patients by flow cytometry and
in vitro suppression assays, in comparison to healthy controls and disease controls (Duchenne’s Muscular Dystrophy).
Presence of Tregs in muscle was analyzed by immunohistochemistry. Overall, Treg percentages in peripheral blood of JDM
patients were similar compared to both control groups. Muscle biopsies of new onset JDM patients showed increased
infiltration of numbers of T cells compared to Duchenne’s muscular dystrophy. Both in JDM and Duchenne’s muscular
dystrophy the proportion of FOXP3+ T cells in muscles were increased compared to JDM peripheral blood. Interestingly,
JDM is not a self-remitting disease, suggesting that the high proportion of Tregs in inflamed muscle do not suppress
inflammation. In line with this, peripheral blood Tregs of active JDM patients were less capable of suppressing effector T cell
activation in vitro, compared to Tregs of JDM in clinical remission. These data show a functional impairment of Tregs in a
proportion of patients with active disease, and suggest a regulatory role for Tregs in JDM inflammation.
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Introduction
Juvenile dermatomyositis (JDM) is a rare systemic immune
mediated inflammatory disease in which the immune system
targets skeletal muscles, skin and sometimes internal organs. The
predominant clinical symptoms are muscle weakness and skin
rash. JDM has an incidence rate of 3.2 per million in patients aged
below 17 in the USA [1] and its cause remains unknown.
JDM is characterized by a highly inflammatory environment
proven by the elevation of different chemokines not only in the
blood but also in the muscle [2–5]. Furthermore, in muscle
biopsies of new onset JDM patients activated CD4+ T cells are
predominantly present, suggesting a pathogenic role for these cells
[6]. CD4+CD25+FOXP3+ regulatory T cells (Tregs) are known to
be potent regulators of T cell mediated autoimmune responses
[7,8]. For instance, in patients with oligoarticular juvenile
idiopathic arthritis (JIA), the presence of Tregs correlates with
favorable disease outcome [9]. Little is known about Tregs in
classical connective tissue diseases. In studies describing Treg
numbers in adults with systemic sclerosis or dermatomyositis,
contrasting results have been found [10–12] and it remains
unclear whether FOXP3 expressing Tregs are present and
functional in JDM patients.
It has been shown that Tregs can lose suppressive capacity in an
inflammatory environment [13–15]. Moreover, under inflamma-
tory conditions human FOXP3+ Tregs express pro-inflammatory
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cytokines such as Interleukin 17 (IL-17) and Interferon c (IFNc)
[16,17]. The current treatment of JDM is based on long term
general immune suppression, resulting in unwarranted side effects,
without curing the disease. As therapies targeting Tregs are
currently being developed, it becomes critical to determine the
functional role of Tregs in JDM.
To establish whether Tregs play a role in the pathogenesis of
JDM, we investigated the presence and function of Tregs in
peripheral blood and inflamed muscle of JDM patients.
Patients and Methods
Ethics statement
JDM patients were followed up at the UMC Utrecht, the
Netherlands, or as part of the JDM Cohort and Biomarker study
and Repository (UK and Ireland). DMD muscle biopsies were
from the MRC Neuromuscular Biobank. This study was
conducted according to the Declaration of Helsinki, and approved
by the institutional review boards: Medisch Ethische Toetsings-
commissie (METC) UMC Utrecht, and Great Ormond Street
Hospital/UCL Institute of Child Health Research Ethics Com-
mittee. Written consent was obtained from all participants, and/or
their parents (NL 34124.041.10).
Participants
JDM patients were included according to the Bohan & Peter
criteria [18]. 5 patients in the active disease group were diagnosed
as JDM patient, but developed in the later follow up a clinical
picture of an overlap syndrome (mainly mixed connective tissue
disease), 1 of this patient was also included in the remission group.
Active disease was defined based on clinical criteria (typical skin
manifestations, muscle involvement proved by abnormal Child-
hood Myositis Assessment Scale (CMAS) score (CMAS,45), and/
or an increase in muscle enzymes: Lactate dehydrogenase (LDH),
Creatine kinase (CK), Aspartate aminotransferase (AST) [19].
Disease remission was defined for this study as the absence of
active inflammation. Healthy children, admitted for minor
urological surgical procedures, served as controls. As disease
controls patients with Duchennes Muscular Dystrophy were
included. Due to evident genetic reasons we could not provide
sex matched controls. Patient characteristics are displayed in
Table 1.
Cells and medium
Peripheral blood mononuclear cells (PBMC) were isolated using
Ficoll Isopaque density gradient centrifugation, frozen in Fetal
Calf Serum (FCS) containing 10% Dimethyl sulfoxide (DMSO),
stored up to 1 month at 280uC and following stored in liquid
nitrogen for 1 month, up to 8 years. Viability of the samples after
thawing was established by trypan blue staining. Samples with .
90% viability were included. RPMI 1640 containing 10 mM
HEPES, 2 mM L-glutamine,100 U/ml penicillin-streptomycin
and 10% human serum was used for culture (Invitrogen, USA).
Flow cytometry
0.5-16106 PBMC/ml were stained using the FOXP3 staining
kit (eBioscience, USA) according to manufacturer’s protocols with
fluorochrome-labeled mAbs against human CD4 (clone RPA-T4),
CD25 (clone 2A3), CD127 (clone hIL-7R-m21) IL-17 (clone N49-
653), and CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4, clone
BN13) (all BD Biosciences, USA), GITR (glucocorticoid-induced
TNFR-related protein, clone 110416, R&D, Germany) and
FOXP3 (clone PCH101, eBioscience, USA), and analyzed by
FACSCanto (BD Biosciences, USA).
IL-17 production was assessed after 3-hour stimulation of cells
at 37uC in the presence of phorbol 12-myristate 13-acetate (PMA)
(0.05 mg/mL), ionomycin (0.5 mg/mL), and brefeldin A (5 mg/mL)
(Sigma-Aldrich, USA).
Suppression assay
10,000 PBMC were stimulated with plate-bound anti-CD3
(clone OKT-3, 1.5 mg/ml, eBioscience, USA). Autologous
CD4+CD25+CD127low T cells were sorted directly into wells of
culture plates by FACS Aria (BD Biosciences, USA) in different
co-culture ratios. Cells were co-cultured for 6 days, the last 18 h
with [3H] thymidine (1 mCi/well). All cultures were performed in
triplo or duplo. Suppressive activity was determined as the relative
difference in proliferative response (mean [3H] counts of triplicate
or duplicate wells) compared to PBMC cultured alone. Lower [3H]
Table 1. Participant characteristics.
PBMC Muscle sections
JDM remission JDM active Controls JDM active DMD
Fig. 1/Fig. 3 Fig. 1/Fig. 3 Fig. 1 Fig. 2 Fig. 2
Number 27/11 21/11 13 8 9
Newly diagnosed - 8/4 - 8 9
Male (percentage) 56/73 38/27 69 38 100
Median age: years (range) 11(8–17)/15 (5–17) 9 (5–17)/13 (6–17) 6 (1–13) 6 (1–11) 5 (2–6)
Therapy 22/6 15/9 0 0 0
Prednisone use 22/5 14/8 - - -
Prednisone low dose (, 0.5 mg/kg/day) 22/5 5/3 - - -
Prednisone high dose (1 mg/kg/day) 0/0 6/2 - - -
High dose corticosteroid pulses (.1 mg/kg) 0/0 3/4 - - -
MTX 13/5 6/1 - - -
IVIG 1/0 1/1 - - -
Other 1/1 2/3 - - -
doi:10.1371/journal.pone.0105353.t001
High Tregs in JDM Muscle Compared to Peripheral Blood
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thymidine incorporation in PBMC+PBMC than PBMC alone
indicates that the increased number of cells decreases proliferation,
leading to exclusion of the assay from the analyses (see Figure S1
and Table S1). Defective suppression is defined as showing no
decrease at all or an increase of proliferation in the presence of the
sorted Tregs, in at least one of the co-culture ratios.
Immunohistochemistry
Muscle biopsies were from the upper leg (m. quadriceps or m.
vastus lateralis). Stainings were performed on acetone-fixed
cryostat-sections with mouse-anti-human CD3 (clone UCHT1,
Nova, USA), followed by HRP Rabbit/Mouse (Dako, UK),
or with biotinylated rat-anti-human FOXP3, followed by
R.T.U.Vectastain kit (Vector Laboratories, UK), and visualized
using 3,3’-Diaminobenzidine. Please note that CD3 staining was
used to stain T cells, since CD4 expression is not specific to T cells
only. 1–4 infiltrated areas were analyzed per patient, depending on
the number of infiltrated areas found in the section. Pictures of
CD3+ and FOXP3+ stainings were taken of infiltrated areas at
206magnification, on consecutive slides with the same infiltrated
area, and for each picture 2 independent researchers counted all
positive cells. The number of cells was adjusted to the number of
pictures counted, to obtain an average number per analyzed area
for each muscle section.
For immunofluorescent staining secondary antibodies used
were: anti-mouse-alexa488, and streptavidin-alexa594 (Invitrogen,
USA), pictures were taken at 206magnification. Stainings of the
paraffin embedded muscle sections for IL-17 and FOXP3 analyses
were performed according to previously published methods [20].
Statistical analysis
Graphs display means 6 Standard Error of the Mean (SEM).
One-way ANOVA analysis (to compare multiple groups, Figure 1)
were used or nonparametric tests Mann Whitney U test (to
compare 2 groups, Figure 2). *P,0.05, **P,0.01.
Results
JDM patients have normal expression of Treg markers in
peripheral blood
In order to establish Treg frequencies in peripheral blood from
JDM patients, we analyzed expression of CD25hi according to
published methods [9], and FOXP3 by CD4+ T cells. For
participant characteristics, see Table 1. JDM patients and controls
displayed similar percentages of CD25hi (Figure 1A, control: 1.3%
60.2 SEM, remission: 1.8% 60.2 SEM, active: 1.8% 60.2 SEM)
and FOXP3 (Figure 1B, control: 7.2% 60.9 SEM, remission:
6.5% 60.5 SEM, active: 7.2% 60.5 SEM) expressing CD4+ T
cells, independent of disease activity. We observed significantly
higher percentages of FOXP3+CD4+ T cells in JDM patients
receiving high corticosteroid treatment (. 1 mg/kg/day, 10.7%
62.0 SEM), compared to patients receiving low (,0.5 mg/kg/
day, 6.1% 60.5 SEM) corticosteroids (Figure 1C, P,0.05). GITR
[21] and CTLA-4 [22] are receptors expressed on Tregs and
involved in Treg suppressive function. The expression of Treg
receptor GITR was not significantly different between healthy
controls and patients (Figure 1D, control: 7.2% 60.9 SEM,
remission: 6.5% 60.5 SEM, active: 7.2% 60.5 SEM), while
CTLA-4 expression was significantly lower in remitting JDM
patients compared to controls, but not significantly different
between active and remitting disease (Figure 1E, control: 61.7%
65.3 SEM, remission: 44.0% 63.5 SEM, active: 50.6% 64.0
Figure 1. Peripheral blood CD4 T cells from JDM patients and age-matched controls have similar expression of Treg markers. PBMC
from JDM patients (JDM) with active (active) or remitting (remission) disease, and controls (control) were isolated and analyzed by flow cytometry (A–
F). (A) Percentage of CD25hi (control N = 13, remission N= 27, active N=21), and (B) FOXP3 (control N= 9, remission N= 27, active N=21) expressing
CD4+ T cells. (C) Percentages of FOXP3 expressing CD4+ T cells in active JDM patients treated with corticosteroids (,0.5 mg/kg N=12, 1 mg/kg N= 6,
.1 mg/kg N=3). Percentages of (D) GITR (control N= 5, remission N= 12, active N= 10), and (E) CTLA-4 (control N= 6, remission N= 15, active N=13)
expressing CD4+ T cells. (F) PBMC from patients with active JDM (at the time of diagnosis, without medication) were stimulated with PMA and
ionomycin and stained for flow cytometry analysis of CD4+ T cells expressing FOXP3 and IL-17 (N= 5). All graphs show mean percentages6 SEM. *P,
0.05, one way ANOVA analysis was used.
doi:10.1371/journal.pone.0105353.g001
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SEM). Though earlier it was reported that human memory T cells
could express both FOXP3 and the inflammatory cytokine IL-17
[16,17], we could hardly detect any FOXP3+IL-17+ T cells
(Figure 1F). Thus, FOXP3+ T cells were present in percentages
similar to controls in peripheral blood of JDM patients and did not
co-express IL-17.
FOXP3+ T cells are abundantly present in inflamed
muscle of patients with active JDM
To investigate whether Tregs are localized at the inflammatory
site, we analyzed muscle biopsies from newly diagnosed JDM
patients before start of treatment, and compared these to biopsies
from Duchenne muscular dystrophy (DMD) patients as non-
autoimmune disease controls. Analysis revealed infiltrates of CD3+
T cells, of which a proportion expressed FOXP3 (Figure 2A).
Numbers of infiltrating T cells (CD3+ and CD3+FOXP3+) per
analysed infiltrates muscle area were significantly higher in muscle
of JDM patients as compared to DMD (Figure 2B, P ,0.05, P,
0.01 respectively). Notably, the percentage of FOXP3 within the
CD3+ T cells, calculated for each patient, did not vary between
JDM (18.5% 63.7 SEM) and DMD (14.3% 63.9 SEM,
Figure 2C). We did not detect any significant correlation with
inflammatory or muscle damage markers, or muscle function
measurements (CRP, CK, LDH, CMAS) and the % FOXP3
expressing cells in the muscle (Figure S2A). Again, Tregs did not
co-express FOXP3 and IL-17 (Figure 2D, showing pictures of 3
separate JDM patients). Thus, compared to peripheral blood
(7.2% 60.5 SEM), high percentages of Tregs (18.5% 63.7 SEM)
were found in inflamed muscle of JDM patients, which seem to be
unable to suppress the ongoing inflammation in the muscle.
Tregs from patients with active JDM exhibit a
compromised suppressive function
Next, we evaluated the suppressive function of the Tregs.
Hereto, CD4+CD25+CD127low T cells from peripheral blood of
JDM patients were sorted. This cell population corresponds at a
Figure 2. FOXP3+ T cells are present in inflamed muscle of newly diagnosed, untreated patients with active JDM. (A) Representative
pictures of both immunohistochemistry single stainings for CD3, a marker for T cells (left), FOXP3 (middle) on consecutive sections from muscle
biopsies (all at 206 magnification, brown-red indicates positive staining), which were used to analyze cell numbers. The right panel shows an
example of immunofluorescence staining (1 out of 4) of a tissue section of a JDM patient, showing FOXP3 (red) expressed in the nuclei of CD3+ T cells
(green). The upper row shows sections of JDM muscle, the second row shows DMD muscle sections. (B) Average numbers of infiltrated CD3+ cells and
FOXP3+ cells, and (C) percentages of CD3+ T cells expressing FOXP3 per section of 8 JDM patients and 9 DMD patients, calculated for each patient, by
counting cells from the immunohistochemistry single stainings on consecutive sections, as described in the methods section. Mean 6 SEM cell
counts: (JDM) CD3 192.7667.9, FOXP3 26.164.8, (DMD) CD3 27.76 4.8, FOXP3 2.961.1, D) Paraffin embedded muscle sections of patients with active
JDM were stained with anti-IL-17 (red), FOXP3 (green) and DAPI (blue). Three representative pictures (206magnification) are shown (N= 3 active JDM
patients, at the time of diagnosis, without medication). All graphs show mean percentages 6 SEM. *P,0.05, **P,0.01, Mann Whitney U test was
used.
doi:10.1371/journal.pone.0105353.g002
High Tregs in JDM Muscle Compared to Peripheral Blood
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e105353
high percentage to FOXP3 expressing cells, confirming the purity
of the sorting (Figure 3A, means 6 SEM. remission 70%6 7
SEM, active 75%6 7 SEM). Tregs from patients in remission
efficiently suppressed effector T cell activation (Figure 3B). Tregs
of 7 patients with active JDM suppressed T cell activation.
However, in 4 patients suppression was absent for the cultures
containing 10_1, and 5_1 ratios of Tregs (Figure 3C). For [3H]
thymidine incorporation data see Figure S1 and Table S1. This
was neither related to onset or prolonged disease status, nor to use
of corticosteroids or other treatments. In addition, we did not
detect any significant correlation with inflammatory or muscle
damage markers, or muscle function measurements (CRP, CK,
ASAT, LDH, CMAS, Figure S2B) though sample size may be too
low to determine significance. Furthermore, there were no
differences in percentages of Tregs, or PBMC composition (data
not shown). Taken together, peripheral blood Tregs from patients
with remitting JDM were functionally normal, whereas Tregs from
patients with active JDM did not consistently suppress effector T
cell responses.
Discussion
JDM is a complex autoimmune disease with a multifactorial
pathogenesis that, among others, involves T cells [6]. In a recently
published study we show that chemokines involved in recruitment
of inflammatory T cells are elevated in the plasma of patients with
active disease onset [3]. Little is known about their pathogenic
role, let alone whether Tregs, which are known to be involved in
the regulation of autoimmunity, are involved in this process. Here
we show the increased presence of Tregs in inflamed muscle of
JDM patients, compared to peripheral blood percentages of Tregs.
The question is whether these cells could influence the course of
JDM. We found no differences in percentages of Tregs between
active and remitting JDM in peripheral blood. Interestingly,
treatment with high levels (.1 mg/kg) of corticosteroids resulted
in increased frequencies of Tregs in active patients. This is in line
with previous reports showing that corticosteroid treatment
increases Treg numbers in Multiple Sclerosis (MS) patients [23]
and in an experimental model for autoimmune encephalomyelitis
(EAE) [24]. The expression of Treg receptors CTLA-4 and GITR
was not significantly different between patients in remission and
patients with active disease. Of note, IL-10 levels in plasma did not
show a difference either [3]. The most relevant test available for
Treg function is the in vitro suppression assay. While Tregs from
patients in remission appeared functionally suppressive, Tregs
from patients with active JDM did not consistently suppress
effector T cells. In 4 out of 11 patient samples, the addition of
Tregs did not change effector T cell proliferation, or even resulted
in increased proliferation. In both patient groups the level of
suppression was variable. Defective suppression was only seen in
the lower ratios of Tregs (10_1 and 5_1), which are more
physiologically relevant, since the higher ratios probably overrule
any defects. Defective suppression was not related to treatment
with corticosteroids, although patient numbers may be too small to
establish a significant effect. A defect in suppressive capacity could
be due to the pro-inflammatory environment in active disease
affecting the function of Tregs in the periphery. In addition,
functional Tregs may have migrated into the inflamed tissue, in
the case of JDM patients to muscle and skin. However, since JDM
is not a self-limiting disease, it is certain that the Tregs present in
the muscle of active JDM patients are not sufficient to control
muscle inflammation. These findings are consistent with reports in
JIA patients; JIA synovial fluid contains high frequencies of
FOXP3+ Tregs, which cannot prevent inflammation [9,25]. This
may be attributed to a defect in Treg function or a transient
upregulation of FOXP3 in non-suppressive T cells. The propor-
tions of FOXP3+ T cells are similar in JDM and DMD muscle,
suggesting that Tregs are able to infiltrate the inflamed muscle
Figure 3. Tregs from patients with active JDM exhibit a compromised suppressive function. (A) Representative dot plots of FOXP3
expression of gated CD4+CD25+CD127low T cells (left dot plot) of JDM patients in remission (middle dot plot), or with active disease (right dot plot),
showing means 6 S.E.M. (B, C) CD4+CD25+CD127low T cells were sorted into co-cultures with anti-CD3 activated autologous PBMC in different ratios.
Proliferation was measured on day 6 by 3H thymidine incorporation. Level of suppression of PBMC proliferation was calculated by comparison to
proliferation of PBMC cultured alone (suppression= 0%). (B) Suppression by CD4+CD25+CD127low T cells from 9 patients in remission and (C) 11
patients with active disease, grey lines represent 4 patients displaying defective suppression in one or more conditions with Tregs present. Defective
suppression is defined as an increased proliferation in the presence of the sorted Tregs, in at least one of the co-culture ratios.
doi:10.1371/journal.pone.0105353.g003
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independent of the underlying cause of inflammation. We do not
see T cell infiltrates in healthy muscle sections (not shown). A
recent study in mouse models of muscle injury and DMD, showed
that Tregs are present in high proportions in the muscle upon
injury and inflammation, while in controls there were very low
numbers of infiltrated cells [26]. Altogether, these mouse models
confirm our finding that high proportions of FOXP3+ T cells
accumulate in muscle upon inflammation.
Under inflammatory conditions human FOXP3+ Tregs co-
express pro-inflammatory cytokines such as IL-17 [16,17]. Even
though IL-17 is implicated in immune pathogenesis of myositis in
adults [27,28], Tregs from JDM patients did not co-express IL-17
in blood or muscle. Of note, IL-17 is not elevated in plasma of
JDM patients either [3]. An alternative explanation for the
impaired suppression observed in active JDM patients, may be
resistance of effector T cells towards Treg-mediated suppression:
Synovial fluid effector T cells from JIA patients could not be
suppressed by Tregs, while the synovial Tregs could suppress
peripheral blood effector T cells [29,30]. In the future, such cross-
over suppression assays should establish whether effector T cells
are resistant to suppression in JDM. The clinical course of JDM
can be either monophasic cyclic or chronic [31],and so far little is
known concerning the immune regulatory effects that may
influence the outcome. Here we have shown that Tregs may be
involved in the regulation of JDM inflammation. Future prospec-
tive studies should determine whether Tregs are able to actively
influence the differential disease course in JDM, and more
importantly, whether manipulation of Tregs and/or resistant
effector T cells could be a therapeutic option in JDM.
Supporting Information
Figure S1 Raw proliferation data of the suppression
assays for each patient. (A) Proliferation of PBMC cultured
with or without Tregs from 9 patients in remission and (B) 11
patients with active disease. Grey lines represent 4 patients
displaying defective suppression (increased proliferation in at least
one of the Treg ratios). Depicted are [3H] thymidine cpm (counts
per minute). Shown are mean 6 SEM of triplo or duplo
measurements per co-culture condition.
(PDF)
Figure S2 Correlation analyses of disease course mark-
ers and Treg percentages and function. (A) Correlation
analyses of disease course markers and Treg percentages in muscle
of JDM patients at active onset. (B) Correlation analysis of disease
course markers and peripheral blood Treg suppressive function in
JDM patients. Analysis was performed for each coculture ratio of
PBMC:Tregs (10:1, 5:1, 2:1, 1:1).
(PDF)
Table S1 Counts per minute (cpm) of 3H thymidine
incorporation of all suppression assays. Depicted are all
raw values of 3H thymidine cpm for each single well analyzed in
the suppression assays. Labeled in blue are the assays displaying
defective suppression in 1 or more conditions with Tregs. Labeled
in grey are the assays we excluded from the analysis in the graphs,
since PBMC+PBMC shows lower proliferation than PBMC alone,
suggesting that merely an increase of cell numbers lowered the
proliferation of the cells.
(PDF)
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